For the past two years, smart glasses were a tech story. In April 2026, they became a prescription eyewear story — and that shift changes everything about who wins, how the products are sold, and what the category is ultimately worth. Three events in the span of three days last week made that transition visible: Meta launched two

America’s largest financial institutions closed out their first-quarter reporting cycle this week with earnings that, by nearly every conventional metric, outperformed what analysts expected. Yet the tone at the top of these institutions told a more cautious story — one that investors would be wise to take seriously alongside the headline numbers. Across JPMorgan, Bank of America, Wells

Micron Technology shares fell roughly 4% in Wednesday afternoon trading as investors took profits, capping a session that otherwise saw the broader market hit record highs. The pullback was a minor stumble relative to what has been a historic month for the chipmaker. Shares are up 40% since the beginning of April, a move that reflects something larger